Brief: Cytrx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided By Licensee Orphazyme A/S
02/05/2019 19:05
CytRx Corp CYTR.O :
* CYTRX CORPORATION HIGHLIGHTS ARIMOCLOMOL CLINICAL
MILESTONE
GUIDANCE PROVIDED BY LICENSEE ORPHAZYME A/S
* CYTRX CORP - CYTRX ELIGIBLE TO RECEIVE UP TO $120 MILLION
IN
FUTURE MILESTONES, PLUS ROYALTIES, FROM ARIMOCLOMOL LICENSING
AGREEMENT
Source text for Eikon: ID:nPn6Qm3LTa
Further company coverage: CYTR.O
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C